Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,509,367
  • Shares Outstanding, K 71,738
  • Annual Sales, $ 55,830 K
  • Annual Income, $ -127,290 K
  • 60-Month Beta 1.38
  • Price/Sales 27.65
  • Price/Cash Flow N/A
  • Price/Book 22.69
Trade CYTK with:

Options Overview

Details
  • Implied Volatility 101.16%
  • Historical Volatility 46.51%
  • IV Percentile 63%
  • IV Rank 17.66%
  • IV High 289.13% on 09/24/20
  • IV Low 60.85% on 10/23/20
  • Put/Call Vol Ratio 0.58
  • Today's Volume 68
  • Volume Avg (30-Day) 269
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 8,467
  • Open Int (30-Day) 7,397

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.65
  • Number of Estimates 4
  • High Estimate -0.58
  • Low Estimate -0.69
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +4.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.23 +4.00%
on 06/07/21
26.18 -19.63%
on 05/17/21
-2.73 (-11.49%)
since 05/11/21
3-Month
20.23 +4.00%
on 06/07/21
28.12 -25.18%
on 04/27/21
+0.74 (+3.65%)
since 03/11/21
52-Week
14.71 +43.03%
on 10/12/20
30.14 -30.19%
on 10/05/20
+0.09 (+0.43%)
since 06/11/20

Most Recent Stories

More News
Cytokinetics to Participate in Upcoming Investor Conferences

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in three virtual fireside chats at the following investor...

CYTK : 21.04 (-2.23%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2021 it granted stock options to purchase an aggregate of 49,500 shares of common stock to eight new employees whose employment...

CYTK : 21.04 (-2.23%)
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS

Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2021 ALS Roundtables and...

CYTK : 21.04 (-2.23%)
Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart...

CYTK : 21.04 (-2.23%)
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records related to heart failure (HF) and hypertrophic cardiomyopathy (HCM)...

CYTK : 21.04 (-2.23%)
Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70 Annual Scientific Session & Expo (ACC.21) taking place online from May 15, 2021 - May...

CYTK : 21.04 (-2.23%)
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.86% and -16.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 21.04 (-2.23%)
Cytokinetics: Q1 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Cytokinetics Inc. (CYTK) on Thursday reported a loss of $47.1 million in its first quarter.

CYTK : 21.04 (-2.23%)
Cytokinetics Reports First Quarter 2021 Financial Results

Secondary Analysis from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session at ACC.21

CYTK : 21.04 (-2.23%)
Cytokinetics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Cytokinetics, Inc. (NASDAQ:CYTK) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern...

CYTK : 21.04 (-2.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 22.48
2nd Resistance Point 22.15
1st Resistance Point 21.59
Last Price 21.04
1st Support Level 20.70
2nd Support Level 20.37
3rd Support Level 19.81

See More

52-Week High 30.14
Fibonacci 61.8% 24.25
Fibonacci 50% 22.42
Last Price 21.04
Fibonacci 38.2% 20.60
52-Week Low 14.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar